董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ian Clark | 男 | Director | 58 | 51.06万美元 | 未持股 | 2018-08-01 |
| Helmy Eltoukhy | 男 | Chief Executive Officer and Director | 39 | 413.61万美元 | 未持股 | 2018-08-01 |
| AmirAli Talasaz | 男 | President, Chief Operating Officer and Chairman of the Board | 39 | 413.61万美元 | 未持股 | 2018-08-01 |
| Stanley Meresman | 男 | Director | 71 | 未披露 | 未持股 | 2018-08-01 |
| Samir Kaul | 男 | Director | 44 | 未披露 | 未持股 | 2018-08-01 |
| Aaref Hilaly | 男 | Director | 47 | 未披露 | 未持股 | 2018-08-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Helmy Eltoukhy | 男 | Chief Executive Officer and Director | 39 | 413.61万美元 | 未持股 | 2018-08-01 |
| AmirAli Talasaz | 男 | President, Chief Operating Officer and Chairman of the Board | 39 | 413.61万美元 | 未持股 | 2018-08-01 |
| Derek Bertocci | 男 | Chief Financial Officer | 64 | 未披露 | 未持股 | 2018-08-01 |
| Richard Lanman | 男 | Chief Medical Officer | 63 | 未披露 | 未持股 | 2018-08-01 |
| Michael Wiley | 男 | Chief Legal Officer | 43 | 99.07万美元 | 未持股 | 2018-08-01 |
| Leena Das Young | 女 | Chief LUNAR Officer and General Manager | 57 | 未披露 | 未持股 | 2018-08-01 |
董事简历
中英对照 | 中文 | 英文- Ian Clark
-
Ian Clark自2020年8月以来一直担任我们的董事会成员。2017年9月至2020年9月，Clark先生曾担任Blackstone Life Sciences（前身为Clarus Ventures，LLC，一家风险投资公司）的运营合伙人。克拉克先生自2019年1月起担任Takeda Pharmaceutical Company Limited上市生物制药公司董事会成员，自2018年1月起担任AVROBIO，Inc.董事，自2017年1月起担任CorvusPharmaceuticals，Inc.董事，自2017年1月起担任GuardantHealth，Inc.董事，自2016年12月起担任Agios制药公司董事。克拉克先生分别于2018年5月至2020年4月和2017年2月至2019年1月担任上市生物制药公司Forty Seven Inc.和Shire Pharmaceuticals，Inc.的董事会成员。他还曾于2017年1月至2017年10月担任KitePharma，Inc.（当时是一家上市生物制药公司）的董事会成员。他曾于2010年1月至2016年12月担任Genentech，Inc.首席执行官。在此之前，他从2009年4月到2009年12月担任罗氏集团执行Vice President和首席营销官。在加入罗氏集团之前，Clark先生从2003年1月到2009年3月在Genentech担任过多个高级管理职位，包括全球产品战略主管、首席营销官、高级副总裁，生物肿瘤学总经理和商业运营执行Vice President。在Genentech之前，Clark先生在生物制药行业工作了23年，在英国，法国和东欧的Novartis International AG，IVAX Pharmaceuticals，Inc.和Sanofi S.A.担任高级职位。他的职业生涯始于孟山都公司（Monsanto Corporation）的子公司G.D.Searle，LLC，在销售与市场营销任职。Clark先生在南汉普顿大学（Southhampton University）获得生物学学士学位。
Ian Clark,has served as Chairperson of Kyverna Therapeutics, Inc. board of directors and as a member of Kyverna Therapeutics, Inc. board of directors since September 2021. Mr. Clark has more than 35 years of experience in the biotechnology and pharmaceutical industry, most recently serving as Chief Executive Officer and member of the board of directors for Genentech, Inc., until his retirement in December 2016. During his seven-year tenure as Chief Executive Officer of Genentech, Mr. Clark and his team brought eleven new medicines to market for patients with rheumatoid arthritis, idiopathic pulmonary fibrosis and various types of cancer. Prior to that, Mr. Clark served as the Executive Vice President and Chief Marketing Officer of the Roche Group from April 2009 to December 2009. Prior to his time at the Roche Group, Mr. Clark held several senior management positions at Genentech Inc. from January 2003 to March 2009, including Head of Global Product Strategy, Chief Marketing Officer, Senior Vice President, General Manager of BioOncology and Executive Vice President, Commercial Operations. Prior to joining Genentech, Mr. Clark spent 23 years in the biopharmaceutical industry holding several positions of increasing responsibility at Novartis AG (NYSE: NVS, SIX: NOVN), Sanofi (Nasdaq: SNY), Ivax and Searle, working in the USA, United Kingdom, Canada, Eastern Europe and France. Currently, Mr. Clark is on the board of directors of several public biopharmaceutical and biotechnology companies: Takeda Pharmaceutical Company Limited (NYSE: TAK), Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), Guardant Health, Inc. (Nasdaq: GH), Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) and Avrobio, Inc. (Nasdaq: AVRO). Mr. Clark previously served on the boards of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), Forty Seven Inc., Shire Pharmaceuticals, Inc., Kite Pharma, Inc., TerraVia Holdings, Inc., Gyroscope Therapeutics Limited, Dendreon Pharmaceuticals LLC and Vernalis (R&D) Limited. He was also on the Board of Biotechnology Industry Association, on the BioFulcrum Board of the Gladstone Institute and on the Economic Advisory Council of the 12th District of the Federal Reserve. In addition, he served as an advisor to Blackstone Life Sciences, formerly Clarus Ventures, LLC, a venture capital firm, from September 2017 to September 2020, as well as to Perella Weinberg Partners LP and Lazard Ltd. Mr. Clark received his Bachelor of Science in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom. - Ian Clark自2020年8月以来一直担任我们的董事会成员。2017年9月至2020年9月，Clark先生曾担任Blackstone Life Sciences（前身为Clarus Ventures，LLC，一家风险投资公司）的运营合伙人。克拉克先生自2019年1月起担任Takeda Pharmaceutical Company Limited上市生物制药公司董事会成员，自2018年1月起担任AVROBIO，Inc.董事，自2017年1月起担任CorvusPharmaceuticals，Inc.董事，自2017年1月起担任GuardantHealth，Inc.董事，自2016年12月起担任Agios制药公司董事。克拉克先生分别于2018年5月至2020年4月和2017年2月至2019年1月担任上市生物制药公司Forty Seven Inc.和Shire Pharmaceuticals，Inc.的董事会成员。他还曾于2017年1月至2017年10月担任KitePharma，Inc.（当时是一家上市生物制药公司）的董事会成员。他曾于2010年1月至2016年12月担任Genentech，Inc.首席执行官。在此之前，他从2009年4月到2009年12月担任罗氏集团执行Vice President和首席营销官。在加入罗氏集团之前，Clark先生从2003年1月到2009年3月在Genentech担任过多个高级管理职位，包括全球产品战略主管、首席营销官、高级副总裁，生物肿瘤学总经理和商业运营执行Vice President。在Genentech之前，Clark先生在生物制药行业工作了23年，在英国，法国和东欧的Novartis International AG，IVAX Pharmaceuticals，Inc.和Sanofi S.A.担任高级职位。他的职业生涯始于孟山都公司（Monsanto Corporation）的子公司G.D.Searle，LLC，在销售与市场营销任职。Clark先生在南汉普顿大学（Southhampton University）获得生物学学士学位。
- Ian Clark,has served as Chairperson of Kyverna Therapeutics, Inc. board of directors and as a member of Kyverna Therapeutics, Inc. board of directors since September 2021. Mr. Clark has more than 35 years of experience in the biotechnology and pharmaceutical industry, most recently serving as Chief Executive Officer and member of the board of directors for Genentech, Inc., until his retirement in December 2016. During his seven-year tenure as Chief Executive Officer of Genentech, Mr. Clark and his team brought eleven new medicines to market for patients with rheumatoid arthritis, idiopathic pulmonary fibrosis and various types of cancer. Prior to that, Mr. Clark served as the Executive Vice President and Chief Marketing Officer of the Roche Group from April 2009 to December 2009. Prior to his time at the Roche Group, Mr. Clark held several senior management positions at Genentech Inc. from January 2003 to March 2009, including Head of Global Product Strategy, Chief Marketing Officer, Senior Vice President, General Manager of BioOncology and Executive Vice President, Commercial Operations. Prior to joining Genentech, Mr. Clark spent 23 years in the biopharmaceutical industry holding several positions of increasing responsibility at Novartis AG (NYSE: NVS, SIX: NOVN), Sanofi (Nasdaq: SNY), Ivax and Searle, working in the USA, United Kingdom, Canada, Eastern Europe and France. Currently, Mr. Clark is on the board of directors of several public biopharmaceutical and biotechnology companies: Takeda Pharmaceutical Company Limited (NYSE: TAK), Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), Guardant Health, Inc. (Nasdaq: GH), Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) and Avrobio, Inc. (Nasdaq: AVRO). Mr. Clark previously served on the boards of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), Forty Seven Inc., Shire Pharmaceuticals, Inc., Kite Pharma, Inc., TerraVia Holdings, Inc., Gyroscope Therapeutics Limited, Dendreon Pharmaceuticals LLC and Vernalis (R&D) Limited. He was also on the Board of Biotechnology Industry Association, on the BioFulcrum Board of the Gladstone Institute and on the Economic Advisory Council of the 12th District of the Federal Reserve. In addition, he served as an advisor to Blackstone Life Sciences, formerly Clarus Ventures, LLC, a venture capital firm, from September 2017 to September 2020, as well as to Perella Weinberg Partners LP and Lazard Ltd. Mr. Clark received his Bachelor of Science in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom.
- Helmy Eltoukhy
-
Helmy Eltoukhy是我们的联合创始人，自2013年1月以来一直担任我们的首席执行官。在创立我们公司之前，Eltoukhy博士从2008年8月到2012年12月在Illumina，Inc.（Illumina）担任过多个职位，包括高级技术研究高级总监，在那里他为遗传分析系统开发了新颖的化学，硬件和信息学。他于2007年6月共同创立Avantome Inc.，将半导体测序商业化，以帮助加快高通量DNA测序的民主化，并担任首席执行官，直到2008年8月被Illumina收购。他于2006年加入Stanford Genome Technology Center，或SGTC，担任博士后，致力于低成本DNA测序技术。在他的博士学习和在SGTC期间，他在几个国家人类基因组研究所（National Human Genome Research Institute）拨款下开发了下一代测序的第一个半导体测序平台和第一个碱基调用算法。他在斯坦福大学（Stanford University）获得电气工程博士、硕士和B.S.学位。
Helmy Eltoukhy is our co-founder and has served as our Chief Executive Officer since January 2013. Prior to founding our company, Dr. Eltoukhy held various positions at Illumina, Inc., or Illumina, from August 2008 to December 2012 including Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. In June 2007 he co-founded Avantome Inc. to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing and served as Chief Executive Officer until its acquisition by Illumina in August 2008. He joined the Stanford Genome Technology Center, or SGTC, as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several National Human Genome Research Institute grants. He received his Ph.D., M.S. and B.S. degrees in electrical engineering from Stanford University. - Helmy Eltoukhy是我们的联合创始人，自2013年1月以来一直担任我们的首席执行官。在创立我们公司之前，Eltoukhy博士从2008年8月到2012年12月在Illumina，Inc.（Illumina）担任过多个职位，包括高级技术研究高级总监，在那里他为遗传分析系统开发了新颖的化学，硬件和信息学。他于2007年6月共同创立Avantome Inc.，将半导体测序商业化，以帮助加快高通量DNA测序的民主化，并担任首席执行官，直到2008年8月被Illumina收购。他于2006年加入Stanford Genome Technology Center，或SGTC，担任博士后，致力于低成本DNA测序技术。在他的博士学习和在SGTC期间，他在几个国家人类基因组研究所（National Human Genome Research Institute）拨款下开发了下一代测序的第一个半导体测序平台和第一个碱基调用算法。他在斯坦福大学（Stanford University）获得电气工程博士、硕士和B.S.学位。
- Helmy Eltoukhy is our co-founder and has served as our Chief Executive Officer since January 2013. Prior to founding our company, Dr. Eltoukhy held various positions at Illumina, Inc., or Illumina, from August 2008 to December 2012 including Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. In June 2007 he co-founded Avantome Inc. to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing and served as Chief Executive Officer until its acquisition by Illumina in August 2008. He joined the Stanford Genome Technology Center, or SGTC, as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several National Human Genome Research Institute grants. He received his Ph.D., M.S. and B.S. degrees in electrical engineering from Stanford University.
- AmirAli Talasaz
-
AmirAli Talasaz是我们的联合创始人和董事会主席，自2013年1月以来一直担任我们的总裁兼首席运营官。创立公司之前，他曾担任Illumina公司的多种职务，包括负责诊断研究的高级董事（从2011年10月到2012年6月），在那里他曾领导下一代基因组分析的新兴临床应用。在那段时间里，他开发了适合临床应用的不同基因组技术。2008年3月，他创立了Auriphex Biosciences，Inc.，专注于循环肿瘤细胞的纯化和遗传分析，用于癌症管理。该技术于2009年被Lllumina收购。在他的学术生涯中，他在SGTC领导技术开发集团。他在斯坦福大学（Stanford University）获得电气工程博士学位、电气工程硕士学位和管理科学与工程硕士学位。
AmirAli Talasaz is our co-founder and chairman of our board of directors and has served as our President and Chief Operating Officer since January 2013. Prior to founding our company, Dr. Talasaz held various positions at Illumina, including Senior Director of Diagnostics Research from October 2011 to June 2012 where he led the efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. In March 2008 he founded Auriphex Biosciences, Inc., which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by lllumina in 2009. During his academic years, he led the Technology Development group at SGTC. He received his Ph.D. degree in electrical engineering, M.S. degree in electrical engineering and M.S. degree in management science and engineering from Stanford University. - AmirAli Talasaz是我们的联合创始人和董事会主席，自2013年1月以来一直担任我们的总裁兼首席运营官。创立公司之前，他曾担任Illumina公司的多种职务，包括负责诊断研究的高级董事（从2011年10月到2012年6月），在那里他曾领导下一代基因组分析的新兴临床应用。在那段时间里，他开发了适合临床应用的不同基因组技术。2008年3月，他创立了Auriphex Biosciences，Inc.，专注于循环肿瘤细胞的纯化和遗传分析，用于癌症管理。该技术于2009年被Lllumina收购。在他的学术生涯中，他在SGTC领导技术开发集团。他在斯坦福大学（Stanford University）获得电气工程博士学位、电气工程硕士学位和管理科学与工程硕士学位。
- AmirAli Talasaz is our co-founder and chairman of our board of directors and has served as our President and Chief Operating Officer since January 2013. Prior to founding our company, Dr. Talasaz held various positions at Illumina, including Senior Director of Diagnostics Research from October 2011 to June 2012 where he led the efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. In March 2008 he founded Auriphex Biosciences, Inc., which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by lllumina in 2009. During his academic years, he led the Technology Development group at SGTC. He received his Ph.D. degree in electrical engineering, M.S. degree in electrical engineering and M.S. degree in management science and engineering from Stanford University.
- Stanley Meresman
-
Stanley Meresman，自2010年9月起担任董事。2004年1月至12月退休，他是Technology Crossover Ventures（一家私人股本公司）的风险合伙人；2001年11月至2003年12月，他是Technology Crossover Ventures的一般合伙人兼首席运营官。在加入Technology Crossover Ventures前的四年间，他是一名独立投资商，也是数家技术公司的董事兼顾问。1989年5月至1997年5月，他是Silicon Graphics, Inc.的高级副总裁兼首席财务官。在Silicon Graphics之前，他是Cypress Semiconductor的财务及行政副总裁兼首席财务官。
Stanley Meresman,Mr. Meresman has served on Snap Inc. board of directors since July 2015. During the last ten years, Mr. Meresman has served on the boards of directors of various public and private companies, including service as chair of the audit committee for some of these companies. He currently serves on the board of directors and as chair of the audit committee of DoorDash, Inc. He served as a member of the board of directors and as chair of the audit committees of Palo Alto Networks, Inc. from September 2014 to December 2018, LinkedIn Corporation from October 2010 to December 2016, Zynga Inc. from June 2011 to June 2015, Medallia, Inc. from June 2015 to October 2021, Guardant Health, Inc. from May 2018 to June 2022, and Cloudflare, Inc. from December 2018 to June 2022; and on the board of directors of Meru Networks, Inc. from September 2010 to May 2013, and Riverbed Technology, Inc. from March 2005 to May 2012. He also serves on the board of trustees of the Panetta Institute of Public Policy, a non-profit organization. From January 2004 to December 2004, Mr. Meresman was a Venture Partner with Technology Crossover Ventures, a private equity firm, and was General Partner and Chief Operating Officer of Technology Crossover Ventures from November 2001 to December 2003. During the four years before joining Technology Crossover Ventures, Mr. Meresman was a private investor and board member and advisor to several technology companies. From 1989 to 1997, Mr. Meresman served as the Senior Vice President and Chief Financial Officer of Silicon Graphics, Inc. Mr. Meresman holds a B.S. in Industrial Engineering and Operations Research from the University of California, Berkeley and an M.B.A. from the Stanford Graduate School of Business. - Stanley Meresman，自2010年9月起担任董事。2004年1月至12月退休，他是Technology Crossover Ventures（一家私人股本公司）的风险合伙人；2001年11月至2003年12月，他是Technology Crossover Ventures的一般合伙人兼首席运营官。在加入Technology Crossover Ventures前的四年间，他是一名独立投资商，也是数家技术公司的董事兼顾问。1989年5月至1997年5月，他是Silicon Graphics, Inc.的高级副总裁兼首席财务官。在Silicon Graphics之前，他是Cypress Semiconductor的财务及行政副总裁兼首席财务官。
- Stanley Meresman,Mr. Meresman has served on Snap Inc. board of directors since July 2015. During the last ten years, Mr. Meresman has served on the boards of directors of various public and private companies, including service as chair of the audit committee for some of these companies. He currently serves on the board of directors and as chair of the audit committee of DoorDash, Inc. He served as a member of the board of directors and as chair of the audit committees of Palo Alto Networks, Inc. from September 2014 to December 2018, LinkedIn Corporation from October 2010 to December 2016, Zynga Inc. from June 2011 to June 2015, Medallia, Inc. from June 2015 to October 2021, Guardant Health, Inc. from May 2018 to June 2022, and Cloudflare, Inc. from December 2018 to June 2022; and on the board of directors of Meru Networks, Inc. from September 2010 to May 2013, and Riverbed Technology, Inc. from March 2005 to May 2012. He also serves on the board of trustees of the Panetta Institute of Public Policy, a non-profit organization. From January 2004 to December 2004, Mr. Meresman was a Venture Partner with Technology Crossover Ventures, a private equity firm, and was General Partner and Chief Operating Officer of Technology Crossover Ventures from November 2001 to December 2003. During the four years before joining Technology Crossover Ventures, Mr. Meresman was a private investor and board member and advisor to several technology companies. From 1989 to 1997, Mr. Meresman served as the Senior Vice President and Chief Financial Officer of Silicon Graphics, Inc. Mr. Meresman holds a B.S. in Industrial Engineering and Operations Research from the University of California, Berkeley and an M.B.A. from the Stanford Graduate School of Business.
- Samir Kaul
-
Samir Kaul，2007年11月起担任本公司董事。2006年2月以来，他是Khosla Ventures的普通合伙人，这是一家专注于清洁技术的风险投资公司。之前，2002年至2006年5月，他曾是风投公司Flagship Ventures的合伙人。加入Flagship之前，他任职于The Institute for Genomic Research。他目前是一些私营公司的董事。他从2013年3月起，担任Gevo的董事；2006-2012，他曾担任Amyris的董事。他获得了University of Michigan的生物学学士学位、University of Maryland的生物化学硕士学位、 Harvard Business School的工商管理硕士学位。
Samir Kaul has served as a member of our Board since January 2021. Mr. Kaul has been a General Partner at Khosla Ventures, a venture capital firm, since February 2006 and currently serves on the boards of directors of several private and public companies, including Guardant Health and Jack Creek Investment Corp. Additionally, Mr. Kaul has served as President, Chief Executive Officer and Director of KV Acquisition I, KV Acquisition III and KV Acquisition IV since their inceptions in January and February 2021. Mr. Kaul holds a B.S. degree in Biology from the University of Michigan, an M.S. degree in Biochemistry from the University of Maryland and an M.B.A. degree from Harvard Business School. - Samir Kaul，2007年11月起担任本公司董事。2006年2月以来，他是Khosla Ventures的普通合伙人，这是一家专注于清洁技术的风险投资公司。之前，2002年至2006年5月，他曾是风投公司Flagship Ventures的合伙人。加入Flagship之前，他任职于The Institute for Genomic Research。他目前是一些私营公司的董事。他从2013年3月起，担任Gevo的董事；2006-2012，他曾担任Amyris的董事。他获得了University of Michigan的生物学学士学位、University of Maryland的生物化学硕士学位、 Harvard Business School的工商管理硕士学位。
- Samir Kaul has served as a member of our Board since January 2021. Mr. Kaul has been a General Partner at Khosla Ventures, a venture capital firm, since February 2006 and currently serves on the boards of directors of several private and public companies, including Guardant Health and Jack Creek Investment Corp. Additionally, Mr. Kaul has served as President, Chief Executive Officer and Director of KV Acquisition I, KV Acquisition III and KV Acquisition IV since their inceptions in January and February 2021. Mr. Kaul holds a B.S. degree in Biology from the University of Michigan, an M.S. degree in Biochemistry from the University of Maryland and an M.B.A. degree from Harvard Business School.
- Aaref Hilaly
-
Aaref Hilaly，2012年6月开始他是我们董事。2012年4月他加入红杉资本公司（Sequoia Capital 创业投资公司）。他目前任职于一些私人公司，包括天网公司（Skyhigh Networks, Inc.）和千眼公司（ ThousandEyes, Inc.）。2011年6月到2012年4月，在加入红杉资本公司（（Sequoia Capital）前，他是 赛门铁克公司（Symantec）的工程部副总裁。2005年4月到2011年6月Clearwell 系统公司被赛门铁克公司（Symantec）收购期间，他是Clearwell 系统公司的首席执行官，这是一个电子发现分析软件的提供者。在这之前，他是centerrun公司（一个后来被太阳微系统公司收购的数据中心自动化的先驱）的创始人和首席执行官。他拥有哈佛大学商学院（Harvard Business School）工商管理学硕士学位和麦克吉尔大学（McGill University）经济学硕士学位，和牛津大学（Oxford University）学士学位。
Aaref Hilaly,as served as one of our directors since June 2012 shortly after joining Sequoia Capital in April 2012. He currently serves on the board of directors of a number of privately-held companies, including Clari and ThousandEyes, Inc. Prior to joining Sequoia Capital, Mr. Hilaly served as Vice President, Engineering at Symantec from June 2011 to April 2012. He was the Chief Executive Officer of Clearwell Systems, Inc. a provider of analytics software for electronic discovery, from April 2005 until Clearwell's acquisition for $410 million by Symantec in June 2011. Prior to that, Mr. Hilaly was the founder and Chief Executive Officer of CenterRun, Inc., a pioneer in datacenter automation, which was acquired by Sun Microsystems, Inc. Mr. Hilaly holds an M.B.A. from Harvard Business School, a Master degree in Economics from McGill University and a B.A. from Oxford University.Mr. Hilaly is a non-managing member of SC XII Management, LLC, an entity associated with Sequoia Capital. Several entities affiliated with Sequoia Capital are stockholders of the Company. - Aaref Hilaly，2012年6月开始他是我们董事。2012年4月他加入红杉资本公司（Sequoia Capital 创业投资公司）。他目前任职于一些私人公司，包括天网公司（Skyhigh Networks, Inc.）和千眼公司（ ThousandEyes, Inc.）。2011年6月到2012年4月，在加入红杉资本公司（（Sequoia Capital）前，他是 赛门铁克公司（Symantec）的工程部副总裁。2005年4月到2011年6月Clearwell 系统公司被赛门铁克公司（Symantec）收购期间，他是Clearwell 系统公司的首席执行官，这是一个电子发现分析软件的提供者。在这之前，他是centerrun公司（一个后来被太阳微系统公司收购的数据中心自动化的先驱）的创始人和首席执行官。他拥有哈佛大学商学院（Harvard Business School）工商管理学硕士学位和麦克吉尔大学（McGill University）经济学硕士学位，和牛津大学（Oxford University）学士学位。
- Aaref Hilaly,as served as one of our directors since June 2012 shortly after joining Sequoia Capital in April 2012. He currently serves on the board of directors of a number of privately-held companies, including Clari and ThousandEyes, Inc. Prior to joining Sequoia Capital, Mr. Hilaly served as Vice President, Engineering at Symantec from June 2011 to April 2012. He was the Chief Executive Officer of Clearwell Systems, Inc. a provider of analytics software for electronic discovery, from April 2005 until Clearwell's acquisition for $410 million by Symantec in June 2011. Prior to that, Mr. Hilaly was the founder and Chief Executive Officer of CenterRun, Inc., a pioneer in datacenter automation, which was acquired by Sun Microsystems, Inc. Mr. Hilaly holds an M.B.A. from Harvard Business School, a Master degree in Economics from McGill University and a B.A. from Oxford University.Mr. Hilaly is a non-managing member of SC XII Management, LLC, an entity associated with Sequoia Capital. Several entities affiliated with Sequoia Capital are stockholders of the Company.
高管简历
中英对照 | 中文 | 英文- Helmy Eltoukhy
Helmy Eltoukhy是我们的联合创始人，自2013年1月以来一直担任我们的首席执行官。在创立我们公司之前，Eltoukhy博士从2008年8月到2012年12月在Illumina，Inc.（Illumina）担任过多个职位，包括高级技术研究高级总监，在那里他为遗传分析系统开发了新颖的化学，硬件和信息学。他于2007年6月共同创立Avantome Inc.，将半导体测序商业化，以帮助加快高通量DNA测序的民主化，并担任首席执行官，直到2008年8月被Illumina收购。他于2006年加入Stanford Genome Technology Center，或SGTC，担任博士后，致力于低成本DNA测序技术。在他的博士学习和在SGTC期间，他在几个国家人类基因组研究所（National Human Genome Research Institute）拨款下开发了下一代测序的第一个半导体测序平台和第一个碱基调用算法。他在斯坦福大学（Stanford University）获得电气工程博士、硕士和B.S.学位。
Helmy Eltoukhy is our co-founder and has served as our Chief Executive Officer since January 2013. Prior to founding our company, Dr. Eltoukhy held various positions at Illumina, Inc., or Illumina, from August 2008 to December 2012 including Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. In June 2007 he co-founded Avantome Inc. to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing and served as Chief Executive Officer until its acquisition by Illumina in August 2008. He joined the Stanford Genome Technology Center, or SGTC, as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several National Human Genome Research Institute grants. He received his Ph.D., M.S. and B.S. degrees in electrical engineering from Stanford University.- Helmy Eltoukhy是我们的联合创始人，自2013年1月以来一直担任我们的首席执行官。在创立我们公司之前，Eltoukhy博士从2008年8月到2012年12月在Illumina，Inc.（Illumina）担任过多个职位，包括高级技术研究高级总监，在那里他为遗传分析系统开发了新颖的化学，硬件和信息学。他于2007年6月共同创立Avantome Inc.，将半导体测序商业化，以帮助加快高通量DNA测序的民主化，并担任首席执行官，直到2008年8月被Illumina收购。他于2006年加入Stanford Genome Technology Center，或SGTC，担任博士后，致力于低成本DNA测序技术。在他的博士学习和在SGTC期间，他在几个国家人类基因组研究所（National Human Genome Research Institute）拨款下开发了下一代测序的第一个半导体测序平台和第一个碱基调用算法。他在斯坦福大学（Stanford University）获得电气工程博士、硕士和B.S.学位。
- Helmy Eltoukhy is our co-founder and has served as our Chief Executive Officer since January 2013. Prior to founding our company, Dr. Eltoukhy held various positions at Illumina, Inc., or Illumina, from August 2008 to December 2012 including Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. In June 2007 he co-founded Avantome Inc. to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing and served as Chief Executive Officer until its acquisition by Illumina in August 2008. He joined the Stanford Genome Technology Center, or SGTC, as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several National Human Genome Research Institute grants. He received his Ph.D., M.S. and B.S. degrees in electrical engineering from Stanford University.
- AmirAli Talasaz
AmirAli Talasaz是我们的联合创始人和董事会主席，自2013年1月以来一直担任我们的总裁兼首席运营官。创立公司之前，他曾担任Illumina公司的多种职务，包括负责诊断研究的高级董事（从2011年10月到2012年6月），在那里他曾领导下一代基因组分析的新兴临床应用。在那段时间里，他开发了适合临床应用的不同基因组技术。2008年3月，他创立了Auriphex Biosciences，Inc.，专注于循环肿瘤细胞的纯化和遗传分析，用于癌症管理。该技术于2009年被Lllumina收购。在他的学术生涯中，他在SGTC领导技术开发集团。他在斯坦福大学（Stanford University）获得电气工程博士学位、电气工程硕士学位和管理科学与工程硕士学位。
AmirAli Talasaz is our co-founder and chairman of our board of directors and has served as our President and Chief Operating Officer since January 2013. Prior to founding our company, Dr. Talasaz held various positions at Illumina, including Senior Director of Diagnostics Research from October 2011 to June 2012 where he led the efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. In March 2008 he founded Auriphex Biosciences, Inc., which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by lllumina in 2009. During his academic years, he led the Technology Development group at SGTC. He received his Ph.D. degree in electrical engineering, M.S. degree in electrical engineering and M.S. degree in management science and engineering from Stanford University.- AmirAli Talasaz是我们的联合创始人和董事会主席，自2013年1月以来一直担任我们的总裁兼首席运营官。创立公司之前，他曾担任Illumina公司的多种职务，包括负责诊断研究的高级董事（从2011年10月到2012年6月），在那里他曾领导下一代基因组分析的新兴临床应用。在那段时间里，他开发了适合临床应用的不同基因组技术。2008年3月，他创立了Auriphex Biosciences，Inc.，专注于循环肿瘤细胞的纯化和遗传分析，用于癌症管理。该技术于2009年被Lllumina收购。在他的学术生涯中，他在SGTC领导技术开发集团。他在斯坦福大学（Stanford University）获得电气工程博士学位、电气工程硕士学位和管理科学与工程硕士学位。
- AmirAli Talasaz is our co-founder and chairman of our board of directors and has served as our President and Chief Operating Officer since January 2013. Prior to founding our company, Dr. Talasaz held various positions at Illumina, including Senior Director of Diagnostics Research from October 2011 to June 2012 where he led the efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. In March 2008 he founded Auriphex Biosciences, Inc., which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by lllumina in 2009. During his academic years, he led the Technology Development group at SGTC. He received his Ph.D. degree in electrical engineering, M.S. degree in electrical engineering and M.S. degree in management science and engineering from Stanford University.
- Derek Bertocci
Derek Bertoccihas自2016年7月起担任我们的首席财务官。在加入我们之前，Bertocci先生于2014年2月至2015年12月担任Achaogen Inc.的高级副总裁兼首席财务官。在此之前，Bertocci先生于2009年1月至2013年9月担任Accuray Incorporated（一家公开交易的放射肿瘤学公司）的高级副总裁兼首席财务官。从2006年10月到2008年12月，Bertocci先生担任Bioform Medical，Inc.的首席财务官，该公司是一家上市的医学美容公司。从2005年6月到2006年7月，他曾担任LaserScope公司（泌尿外科和美容手术的激光和光纤设备的上市供应商）的首席财务官。在此之前，Bertocci先生曾在Visx Incorporated（一家公开上市的激光视力矫正手术系统提供商）担任多年的各种职务，包括2004年3月至2005年5月担任首席财务官，1998年至2004年3月担任Vice President兼财务总监。Bertocci先生拥有斯坦福大学（Stanford University）的学士学位和南加州大学（University of Southern California）的工商管理硕士学位。Bertocci先生也是一名不活跃的注册会计师。
Derek Bertoccihas served as our Chief Financial Officer since July 2016. Prior to joining us, Mr. Bertocci served as Senior Vice President and Chief Financial Officer of Achaogen Inc. from February 2014 to December 2015. Prior to that, Mr. Bertocci was Senior Vice President and Chief Financial Officer of Accuray Incorporated, a publicly traded radiation oncology company, from January 2009 to September 2013. From October 2006 through December 2008 Mr. Bertocci served as the Chief Financial Officer of BioForm Medical, Inc., a publicly traded medical aesthetics company. From June 2005 to July 2006 he was Chief Financial Officer of Laserscope, a publicly traded provider of lasers and fiber optic devices for urology and aesthetic surgery. Prior to that, Mr. Bertocci spent a number of years in various roles at VISX Incorporated, a publicly traded provider of systems for laser vision correction surgery, including as Chief Financial Officer from March 2004 to May 2005 and Vice President and Controller from 1998 to March 2004. Mr. Bertocci holds a B.A. degree from Stanford University and an M.B.A. degree from the University of Southern California. Mr. Bertocci is also a Certified Public Accountant inactive.- Derek Bertoccihas自2016年7月起担任我们的首席财务官。在加入我们之前，Bertocci先生于2014年2月至2015年12月担任Achaogen Inc.的高级副总裁兼首席财务官。在此之前，Bertocci先生于2009年1月至2013年9月担任Accuray Incorporated（一家公开交易的放射肿瘤学公司）的高级副总裁兼首席财务官。从2006年10月到2008年12月，Bertocci先生担任Bioform Medical，Inc.的首席财务官，该公司是一家上市的医学美容公司。从2005年6月到2006年7月，他曾担任LaserScope公司（泌尿外科和美容手术的激光和光纤设备的上市供应商）的首席财务官。在此之前，Bertocci先生曾在Visx Incorporated（一家公开上市的激光视力矫正手术系统提供商）担任多年的各种职务，包括2004年3月至2005年5月担任首席财务官，1998年至2004年3月担任Vice President兼财务总监。Bertocci先生拥有斯坦福大学（Stanford University）的学士学位和南加州大学（University of Southern California）的工商管理硕士学位。Bertocci先生也是一名不活跃的注册会计师。
- Derek Bertoccihas served as our Chief Financial Officer since July 2016. Prior to joining us, Mr. Bertocci served as Senior Vice President and Chief Financial Officer of Achaogen Inc. from February 2014 to December 2015. Prior to that, Mr. Bertocci was Senior Vice President and Chief Financial Officer of Accuray Incorporated, a publicly traded radiation oncology company, from January 2009 to September 2013. From October 2006 through December 2008 Mr. Bertocci served as the Chief Financial Officer of BioForm Medical, Inc., a publicly traded medical aesthetics company. From June 2005 to July 2006 he was Chief Financial Officer of Laserscope, a publicly traded provider of lasers and fiber optic devices for urology and aesthetic surgery. Prior to that, Mr. Bertocci spent a number of years in various roles at VISX Incorporated, a publicly traded provider of systems for laser vision correction surgery, including as Chief Financial Officer from March 2004 to May 2005 and Vice President and Controller from 1998 to March 2004. Mr. Bertocci holds a B.A. degree from Stanford University and an M.B.A. degree from the University of Southern California. Mr. Bertocci is also a Certified Public Accountant inactive.
- Richard Lanman
Richard Lanman自2014年9月以来一直担任我们的首席医疗官。在加入我们之前，Lanman博士从2008年7月到2014年9月担任Veracyte，Inc.首席医疗官，在那里他管理与学术和基于社区的医生思想领袖的合作，并领导研究和出版物，从而为AFIRMA甲状腺癌测试提供了广泛的管理式医疗覆盖。在此之前，他从2005年4月到2008年7月担任Diadexus，Inc.的首席医疗官，从2000年11月到2005年3月担任Atherotech，Inc.的首席医疗官。在加入Atherotech，Inc.之前，Lanman博士从1993年10月到1995年4月担任圣何塞医疗集团的医疗总监和高级副总裁，从1985年7月到1993年9月担任Kaiser Permanente的质量主管。Lanman博士在西北大学（Northwestern University）获得医学博士学位，在斯坦福大学（Stanford University）获得化学B.S.学位。
Richard Lanman has served as our Chief Medical Officer since September 2014. Prior to joining us, Dr. Lanman served as Chief Medical Officer of Veracyte, Inc. from July 2008 to September 2014 where he managed collaborations with academic and community-based physician thought leaders and led studies and publications resulting in broad managed care coverage for the Afirma thyroid cancer test. Prior to that, he served as Chief Medical Officer of diaDexus, Inc. from April 2005 to July 2008 and of Atherotech, Inc. from November 2000 to March 2005. Prior to Atherotech, Inc., Dr. Lanman was the Medical Director and Senior Vice President of San Jose Medical Group from October 1993 to April 1995 and the Chief of Quality at Kaiser Permanente from July 1985 to September 1993. Dr. Lanman received his M.D. degree from Northwestern University and a B.S. degree in chemistry from Stanford University.- Richard Lanman自2014年9月以来一直担任我们的首席医疗官。在加入我们之前，Lanman博士从2008年7月到2014年9月担任Veracyte，Inc.首席医疗官，在那里他管理与学术和基于社区的医生思想领袖的合作，并领导研究和出版物，从而为AFIRMA甲状腺癌测试提供了广泛的管理式医疗覆盖。在此之前，他从2005年4月到2008年7月担任Diadexus，Inc.的首席医疗官，从2000年11月到2005年3月担任Atherotech，Inc.的首席医疗官。在加入Atherotech，Inc.之前，Lanman博士从1993年10月到1995年4月担任圣何塞医疗集团的医疗总监和高级副总裁，从1985年7月到1993年9月担任Kaiser Permanente的质量主管。Lanman博士在西北大学（Northwestern University）获得医学博士学位，在斯坦福大学（Stanford University）获得化学B.S.学位。
- Richard Lanman has served as our Chief Medical Officer since September 2014. Prior to joining us, Dr. Lanman served as Chief Medical Officer of Veracyte, Inc. from July 2008 to September 2014 where he managed collaborations with academic and community-based physician thought leaders and led studies and publications resulting in broad managed care coverage for the Afirma thyroid cancer test. Prior to that, he served as Chief Medical Officer of diaDexus, Inc. from April 2005 to July 2008 and of Atherotech, Inc. from November 2000 to March 2005. Prior to Atherotech, Inc., Dr. Lanman was the Medical Director and Senior Vice President of San Jose Medical Group from October 1993 to April 1995 and the Chief of Quality at Kaiser Permanente from July 1985 to September 1993. Dr. Lanman received his M.D. degree from Northwestern University and a B.S. degree in chemistry from Stanford University.
- Michael Wiley
Michael Wiley自2016年7月起担任我们的首席法务官。他曾于2012年7月至2013年1月担任我们的总裁，并于2013年1月至2016年7月担任我们的首席财务官。在加入我们公司之前，Wiley先生从2008年8月到2009年4月担任医疗设备公司Voyage Medical Inc.的财务和法律Vice President，然后从2009年4月到2012年7月担任首席财务官。此前，他曾担任Microchip Biotechnologies公司的财务Vice President（从2006年5月到2008年8月）。职业生涯早期，他曾担任Venture Law Group的公司律师，也曾担任Novell，Inc.公司的内部副法律顾问，在那里他专注于知识产权和就业问题。他也曾任职KPMG LLP，担任税务会计师。Wiley先生在杨百翰大学（Brigham Young University）的J.Reuben Clark法学院获得法学博士学位，并在杨百翰大学（Brigham Young University）获得会计学B.S.学位。
Michael Wiley has served as our Chief Legal Officer since July 2016. He previously served as our President from July 2012 to January 2013 and as our Chief Financial Officer from January 2013 to July 2016. Prior to joining our company, Mr. Wiley served as Vice President of Finance and Legal of Voyage Medical Inc., a medical device company, from August 2008 to April 2009 and then as Chief Financial Officer from April 2009 to July 2012. Prior to that, he was Vice President of Finance at Microchip Biotechnologies, Inc. from May 2006 to August 2008. Earlier in his career, he was a corporate attorney at Venture Law Group and acted as in-house associate counsel for Novell, Inc., where he focused on intellectual property and employment issues. He also worked for KPMG LLP as a tax accountant. Mr. Wiley received a J.D. degree from the J. Reuben Clark Law School at Brigham Young University and a B.S. degree in accounting from Brigham Young University.- Michael Wiley自2016年7月起担任我们的首席法务官。他曾于2012年7月至2013年1月担任我们的总裁，并于2013年1月至2016年7月担任我们的首席财务官。在加入我们公司之前，Wiley先生从2008年8月到2009年4月担任医疗设备公司Voyage Medical Inc.的财务和法律Vice President，然后从2009年4月到2012年7月担任首席财务官。此前，他曾担任Microchip Biotechnologies公司的财务Vice President（从2006年5月到2008年8月）。职业生涯早期，他曾担任Venture Law Group的公司律师，也曾担任Novell，Inc.公司的内部副法律顾问，在那里他专注于知识产权和就业问题。他也曾任职KPMG LLP，担任税务会计师。Wiley先生在杨百翰大学（Brigham Young University）的J.Reuben Clark法学院获得法学博士学位，并在杨百翰大学（Brigham Young University）获得会计学B.S.学位。
- Michael Wiley has served as our Chief Legal Officer since July 2016. He previously served as our President from July 2012 to January 2013 and as our Chief Financial Officer from January 2013 to July 2016. Prior to joining our company, Mr. Wiley served as Vice President of Finance and Legal of Voyage Medical Inc., a medical device company, from August 2008 to April 2009 and then as Chief Financial Officer from April 2009 to July 2012. Prior to that, he was Vice President of Finance at Microchip Biotechnologies, Inc. from May 2006 to August 2008. Earlier in his career, he was a corporate attorney at Venture Law Group and acted as in-house associate counsel for Novell, Inc., where he focused on intellectual property and employment issues. He also worked for KPMG LLP as a tax accountant. Mr. Wiley received a J.D. degree from the J. Reuben Clark Law School at Brigham Young University and a B.S. degree in accounting from Brigham Young University.
- Leena Das Young
Leena Das Young自2018年6月起担任我们的首席登月官兼总经理。在加入我们之前，她曾于2013年11月至2018年6月担任多个辉瑞公司（Pfizer）肿瘤科的Vice President兼后期开发主管，负责实体肿瘤和血液恶性肿瘤的肿瘤药物组合。她也曾担任高级商业领袖（从2008年11月到2010年6月），以及美国商业领袖（从2003年6月到2008年10月），在那里她曾监管肿瘤产品的商业开发、营销和推出。任职Pfizer公司之前，她曾于2001年11月至2003年5月担任Eximias Pharmaceutical Corporation的营销Vice President。她获得了药剂学和药剂学学士学位。Purdue University学位。
Leena Das Young has served as our Chief LUNAR Officer and General Manager since June 2018. Prior to joining us, she served as Vice President and Head of Late Phase Development for various Pfizer Inc., or Pfizer, oncology departments from November 2013 to June 2018 where she oversaw a portfolio of oncology drugs for solid tumors and hematologic malignancies. She also served as a senior commercial leader from November 2008 to June 2010 and as a U.S. commercial leader from June 2003 to October 2008 where she oversaw the commercial development, marketing and launch of oncology products. Before her work at Pfizer, she served as the Vice President of Marketing at Eximias Pharmaceutical Corporation from November 2001 to May 2003. She received her B.S. degree in pharmacy and Pharm.D. degree from Purdue University.- Leena Das Young自2018年6月起担任我们的首席登月官兼总经理。在加入我们之前，她曾于2013年11月至2018年6月担任多个辉瑞公司（Pfizer）肿瘤科的Vice President兼后期开发主管，负责实体肿瘤和血液恶性肿瘤的肿瘤药物组合。她也曾担任高级商业领袖（从2008年11月到2010年6月），以及美国商业领袖（从2003年6月到2008年10月），在那里她曾监管肿瘤产品的商业开发、营销和推出。任职Pfizer公司之前，她曾于2001年11月至2003年5月担任Eximias Pharmaceutical Corporation的营销Vice President。她获得了药剂学和药剂学学士学位。Purdue University学位。
- Leena Das Young has served as our Chief LUNAR Officer and General Manager since June 2018. Prior to joining us, she served as Vice President and Head of Late Phase Development for various Pfizer Inc., or Pfizer, oncology departments from November 2013 to June 2018 where she oversaw a portfolio of oncology drugs for solid tumors and hematologic malignancies. She also served as a senior commercial leader from November 2008 to June 2010 and as a U.S. commercial leader from June 2003 to October 2008 where she oversaw the commercial development, marketing and launch of oncology products. Before her work at Pfizer, she served as the Vice President of Marketing at Eximias Pharmaceutical Corporation from November 2001 to May 2003. She received her B.S. degree in pharmacy and Pharm.D. degree from Purdue University.